Goldman Sachs raised the firm’s price target on Viridian Therapeutics (VRDN) to $40 from $30 and keeps a Buy rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics: Promising Future with Strategic Trials and Financial Stability
- Viridian Therapeutics reports Q3 EPS (34c), consensus (94c)
- Viridian Therapeutics: Promising Future with Strategic Advancements and Financial Backing
- Viridian Therapeutics: Promising Prospects with Innovative TED Treatments and Financial Stability Justify Buy Rating
- Viridian Therapeutics submits BLA to the FDA for veligrotug